Review





Similar Products

96
Addgene inc cas9 sgrna co expression plasmids
Cas9 Sgrna Co Expression Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/pSpCas9(BB)-2A-Puro+(PX459)+V2%2E0+(Plasmid+%2362988)/bio_rxiv__64898__2026__10__31__763349-157-21-25
Average 96 stars, based on 1 article reviews
cas9 sgrna co expression plasmids - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Addgene inc lentiviral crispri plasmid encoding nuclease dead cas9
Lentiviral Crispri Plasmid Encoding Nuclease Dead Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/pLV+hU6-sgRNA+hUbC-dCas9-KRAB-T2a-Puro+(Plasmid+%2371236)/pm42963426-436-4-30
Average 96 stars, based on 1 article reviews
lentiviral crispri plasmid encoding nuclease dead cas9 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Addgene inc pcu6 3 sgrna williams et
Pcu6 3 Sgrna Williams Et, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/pCAG+Cas9-2A-Citrine+(Plasmid+%2392358)/pm42844404-300-39-37
Average 93 stars, based on 1 article reviews
pcu6 3 sgrna williams et - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology small guide rnas sgrnas
(A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing <t>RNAs;</t> ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .
Small Guide Rnas Sgrnas, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/Nanos3+CRISPR%2FCas9+KO+Plasmid/pmc13641165-565-6-10
Average 93 stars, based on 1 article reviews
small guide rnas sgrnas - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Addgene inc crispr cas9 sgrna vector pdd162
(A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing <t>RNAs;</t> ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .
Crispr Cas9 Sgrna Vector Pdd162, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/pDD162+(Peft-3%3A%3ACas9+%2B+Empty+sgRNA)+(Plasmid+%2347549)/pm42771683-522-13-16
Average 95 stars, based on 1 article reviews
crispr cas9 sgrna vector pdd162 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
New England Biolabs sgrnas
(A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing <t>RNAs;</t> ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .
Sgrnas, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/Cas9+Nuclease%2C+S%2E+pyogenes/pm42611132-89-10-16
Average 96 stars, based on 1 article reviews
sgrnas - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

86
Benchling Inc cas9 sgrna mg17
(A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing <t>RNAs;</t> ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .
Cas9 Sgrna Mg17, supplied by Benchling Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/crispr+design+tool/pm42269836-382-52-54
Average 86 stars, based on 1 article reviews
cas9 sgrna mg17 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
Addgene inc pst1374 n nls flag linker cas9 d10a plasmids
(A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing <t>RNAs;</t> ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .
Pst1374 N Nls Flag Linker Cas9 D10a Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/pGL3-U6-sgRNA-PGK-puromycin+(Plasmid+%2351133)/pm42020726-44-3-10
Average 94 stars, based on 1 article reviews
pst1374 n nls flag linker cas9 d10a plasmids - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Applied Biological Materials Inc one sgrna crispr cas9 lentivectors
A. Western blot confirmation of loss of Orai1 expression upon <t>CRISPR/Cas9-mediated</t> KO in MDA-MB-231 and Hs578T cells; shown are pools of three clones maintained individually. B-C. Impairment of SOCE upon Orai1 KO in TNBC cells. SOCE was measured using thapsigargin-induced ER Ca 2+ depletion. Typical profiles are shown on left and quantification of fold-change in peak fluorescence intensity from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. D-E. Orai1-KO impairs the repair of mechanically induced plasma membrane injury. WT vs. Orai1-KO cells were subjected to mechanical injury to plasma membrane and repair assay was performed as in . Representative confocal images are shown in D and quantified data are shown in E. Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. F-G. Orai1-KO impairs the repair of SLO-induced membrane injury. Plasma membrane damage using SLO and the repair assay on MDA-MB-231 ( F ) and Hs578T ( G ) cell lines were as in . Representative confocal images are shown on left. Quantification of PI-stained cells from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. H-J. Orai1 inhibitors impair plasma membrane repair. Panel H shows Thapsigargin (TG)-induced SOCE measurements (initial peak, Ca 2+ store release in the absence of extracellular Ca 2+ ; second peak, SOCE in the presence of extracellular Ca 2+ ) performed on the indicated cell lines cultured with or without CM4620 (10 μM, 4 hours pretreatment). Note significant SOCE inhibition by CM4620 in WT cells but not in Orai1-KO cells, supporting Orai1-selelctive effect of CM4620. Data represents mean +/- SEM of three experiments, Welch’s t test, ***p<0.001. The I panel shows the impairment of mechanically induced plasma membrane repair by CM4620 in MDA-MB-231. Cells were cultured without or with pretreatment with CM4620 (10 μM) and analyzed for repair as in . Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. The J panel shows the impairment of SLO-induced membrane damage in MDA-MB-231. Left panel shows representative FACS analysis of membrane repair in cells without or with CM4620 treatment. Right panel shows quantification of cells that failed to repair (PI staining) from 3 independent experiments. Data represents mean +/-SEM of three experiments. Welch’s t test, ***, p<0.001.
One Sgrna Crispr Cas9 Lentivectors, supplied by Applied Biological Materials Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/293t+cells/bio_rxiv__64898__2026__05__13__724989-192-0-5
Average 86 stars, based on 1 article reviews
one sgrna crispr cas9 lentivectors - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Genechem cas9 sgrna plasmids
A. Western blot confirmation of loss of Orai1 expression upon <t>CRISPR/Cas9-mediated</t> KO in MDA-MB-231 and Hs578T cells; shown are pools of three clones maintained individually. B-C. Impairment of SOCE upon Orai1 KO in TNBC cells. SOCE was measured using thapsigargin-induced ER Ca 2+ depletion. Typical profiles are shown on left and quantification of fold-change in peak fluorescence intensity from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. D-E. Orai1-KO impairs the repair of mechanically induced plasma membrane injury. WT vs. Orai1-KO cells were subjected to mechanical injury to plasma membrane and repair assay was performed as in . Representative confocal images are shown in D and quantified data are shown in E. Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. F-G. Orai1-KO impairs the repair of SLO-induced membrane injury. Plasma membrane damage using SLO and the repair assay on MDA-MB-231 ( F ) and Hs578T ( G ) cell lines were as in . Representative confocal images are shown on left. Quantification of PI-stained cells from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. H-J. Orai1 inhibitors impair plasma membrane repair. Panel H shows Thapsigargin (TG)-induced SOCE measurements (initial peak, Ca 2+ store release in the absence of extracellular Ca 2+ ; second peak, SOCE in the presence of extracellular Ca 2+ ) performed on the indicated cell lines cultured with or without CM4620 (10 μM, 4 hours pretreatment). Note significant SOCE inhibition by CM4620 in WT cells but not in Orai1-KO cells, supporting Orai1-selelctive effect of CM4620. Data represents mean +/- SEM of three experiments, Welch’s t test, ***p<0.001. The I panel shows the impairment of mechanically induced plasma membrane repair by CM4620 in MDA-MB-231. Cells were cultured without or with pretreatment with CM4620 (10 μM) and analyzed for repair as in . Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. The J panel shows the impairment of SLO-induced membrane damage in MDA-MB-231. Left panel shows representative FACS analysis of membrane repair in cells without or with CM4620 treatment. Right panel shows quantification of cells that failed to repair (PI staining) from 3 independent experiments. Data represents mean +/-SEM of three experiments. Welch’s t test, ***, p<0.001.
Cas9 Sgrna Plasmids, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cas9+sgrna/cas9+plasmids+sgrna/pm42115618-367-0-5
Average 86 stars, based on 1 article reviews
cas9 sgrna plasmids - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


(A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing RNAs; ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .

Journal: Molecular cell

Article Title: DND1–NANOS3 shapes the PGC transcriptome via a heptanucleotide sequence in mRNA 3′-UTRs

doi: 10.1016/j.molcel.2026.09.010

Figure Lengend Snippet: (A) DND1 (purple) and NANOS3 (pink) residues interacting with the N3-DRE. Filled shading, residues substituted with alanine for functional analysis. (B) DND1–NANOS3 co-expression constructs with indicated mutations (top) or truncations (bottom). (C) Schematic of assays performed with cells expressing constructs from (B). (D) Assay results for DND1–NANOS3 constructs with DND1 point mutants: ( 1 ) IncuCyte growth assays; ( 2 ) expression of N3-DRE-containing RNAs; ( 3 ) protein levels of N3-DRE-containing targets (CDK1, EHMT2, and CNOT6; immunoblots in Fig. S5 ). (E) As in (D), with NANOS3 point mutations. (F) DND1 K196A loses selectivity for the N3-DRE G3 nucleotide in vitro . Error bars, K d confidence interval from MST data fitting. (G) As in (D), with DND1 or NANOS3 truncations. (H) Effects of DND1/NANOS3 mutations or deletions on RNA turnover. Left, median fold changes in k deg for each N3-DRE class, normalized to the corresponding No motif group. Middle, median fold changes in k syn . Right, median fold changes in transcript half-life. Corresponding violin plots and CDFs are shown in Figures S5F and S5G . (I) Summary of the functional impact of RNA-binding residue mutations and IDR deletion. Statistics (D-F): Cell growth: Scale bar, 400 μm (bottom right image only). CDFs: n, number of genes; ML, median log 2 -fold change; δ, Cliff’s delta; p , two-sided Wilcoxon rank-sum test. Protein quantification: Error bars indicate S.D. Two-sided Student’s t -test ( n = 3 independent experiments). Exact p -values are provided in Source Data. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. See also Figure S5 and Table S1 .

Article Snippet: We purchased a cocktail of three small guide RNAs (sgRNAs) (Santa Cruz Biotechnology, Inc., sc-434074), cloned individual sgRNA plasmids, and used pairs of the sgRNAs for the targeted deletions of the ZF region of the Nanos3 locus.

Techniques: RNA Binding Assay, Functional Assay, Analysis, Expressing, Construct, Western Blot, In Vitro, Residue

A. Western blot confirmation of loss of Orai1 expression upon CRISPR/Cas9-mediated KO in MDA-MB-231 and Hs578T cells; shown are pools of three clones maintained individually. B-C. Impairment of SOCE upon Orai1 KO in TNBC cells. SOCE was measured using thapsigargin-induced ER Ca 2+ depletion. Typical profiles are shown on left and quantification of fold-change in peak fluorescence intensity from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. D-E. Orai1-KO impairs the repair of mechanically induced plasma membrane injury. WT vs. Orai1-KO cells were subjected to mechanical injury to plasma membrane and repair assay was performed as in . Representative confocal images are shown in D and quantified data are shown in E. Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. F-G. Orai1-KO impairs the repair of SLO-induced membrane injury. Plasma membrane damage using SLO and the repair assay on MDA-MB-231 ( F ) and Hs578T ( G ) cell lines were as in . Representative confocal images are shown on left. Quantification of PI-stained cells from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. H-J. Orai1 inhibitors impair plasma membrane repair. Panel H shows Thapsigargin (TG)-induced SOCE measurements (initial peak, Ca 2+ store release in the absence of extracellular Ca 2+ ; second peak, SOCE in the presence of extracellular Ca 2+ ) performed on the indicated cell lines cultured with or without CM4620 (10 μM, 4 hours pretreatment). Note significant SOCE inhibition by CM4620 in WT cells but not in Orai1-KO cells, supporting Orai1-selelctive effect of CM4620. Data represents mean +/- SEM of three experiments, Welch’s t test, ***p<0.001. The I panel shows the impairment of mechanically induced plasma membrane repair by CM4620 in MDA-MB-231. Cells were cultured without or with pretreatment with CM4620 (10 μM) and analyzed for repair as in . Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. The J panel shows the impairment of SLO-induced membrane damage in MDA-MB-231. Left panel shows representative FACS analysis of membrane repair in cells without or with CM4620 treatment. Right panel shows quantification of cells that failed to repair (PI staining) from 3 independent experiments. Data represents mean +/-SEM of three experiments. Welch’s t test, ***, p<0.001.

Journal: bioRxiv

Article Title: Orai1 is required for Ca 2+ -dependent plasma membrane repair and mechanoadaptation

doi: 10.64898/2026.05.13.724989

Figure Lengend Snippet: A. Western blot confirmation of loss of Orai1 expression upon CRISPR/Cas9-mediated KO in MDA-MB-231 and Hs578T cells; shown are pools of three clones maintained individually. B-C. Impairment of SOCE upon Orai1 KO in TNBC cells. SOCE was measured using thapsigargin-induced ER Ca 2+ depletion. Typical profiles are shown on left and quantification of fold-change in peak fluorescence intensity from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. D-E. Orai1-KO impairs the repair of mechanically induced plasma membrane injury. WT vs. Orai1-KO cells were subjected to mechanical injury to plasma membrane and repair assay was performed as in . Representative confocal images are shown in D and quantified data are shown in E. Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. F-G. Orai1-KO impairs the repair of SLO-induced membrane injury. Plasma membrane damage using SLO and the repair assay on MDA-MB-231 ( F ) and Hs578T ( G ) cell lines were as in . Representative confocal images are shown on left. Quantification of PI-stained cells from 3 independent experiments is shown on right. Welch’s t test, ***p<0.001. H-J. Orai1 inhibitors impair plasma membrane repair. Panel H shows Thapsigargin (TG)-induced SOCE measurements (initial peak, Ca 2+ store release in the absence of extracellular Ca 2+ ; second peak, SOCE in the presence of extracellular Ca 2+ ) performed on the indicated cell lines cultured with or without CM4620 (10 μM, 4 hours pretreatment). Note significant SOCE inhibition by CM4620 in WT cells but not in Orai1-KO cells, supporting Orai1-selelctive effect of CM4620. Data represents mean +/- SEM of three experiments, Welch’s t test, ***p<0.001. The I panel shows the impairment of mechanically induced plasma membrane repair by CM4620 in MDA-MB-231. Cells were cultured without or with pretreatment with CM4620 (10 μM) and analyzed for repair as in . Scale bar, 200 µm. Data represents mean +/- SEM of three experiments, two-way ANOVA, **,p<0.01. The J panel shows the impairment of SLO-induced membrane damage in MDA-MB-231. Left panel shows representative FACS analysis of membrane repair in cells without or with CM4620 treatment. Right panel shows quantification of cells that failed to repair (PI staining) from 3 independent experiments. Data represents mean +/-SEM of three experiments. Welch’s t test, ***, p<0.001.

Article Snippet: All-in-One sgRNA CRISPR/Cas9 Lentivectors from Applied Biological Materials (Richmond, BC, Canada) were used to derive Orai1 (pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro, #35720125) KO cell lines.

Techniques: Western Blot, Expressing, CRISPR, Clone Assay, Fluorescence, Clinical Proteomics, Membrane, Staining, Cell Culture, Inhibition